Statins as primary prevention in patients without dislipidaemia

Cardiovascular disease (CVD) remains the leading cause of death in Australia, responsible for 34% and 39% of male and female deaths, respectively. It is also a significant contributor to the burden of disease across the population, Dyslipidaemia, especially elevated levels of lOW-density lipoprotein cholesterol (LDL-Cl, is recognised as a major cardiovascular risk factor. Statins have become firmly established as first-line lipid lowering therapy in the secondary prevention of established CVD due to their ability to lower LDL-C levels and improve patient outcomes